Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD: A GENFI study

Raphael Schneider, Paul McKeever, Taehyung Kim, Caroline Graff, John Cornelis Van Swieten, Anna Karydas, Adam Boxer, Howie Rosen, Bruce L. Miller, Robert Laforce, Daniela Galimberti, Mario Masellis, Barbara Borroni, Zhaolei Zhang, Lorne Zinman, Jonathan Daniel Rohrer, Maria Carmela Tartaglia, Janice Robertson

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: To determine whether exosomal microRNAs (miRNAs) in cerebrospinal fluid (CSF) of patients with frontotemporal dementia (FTD) can serve as diagnostic biomarkers, we assessed miRNA expression in the Genetic Frontotemporal Dementia Initiative (GENFI) cohort and in sporadic FTD. Methods: GENFI participants were either carriers of a pathogenic mutation in progranulin, chromosome 9 open reading frame 72 or microtubule-associated protein tau or were at risk of carrying a mutation because a first-degree relative was a known symptomatic mutation carrier. Exosomes were isolated from CSF of 23 presymptomatic and 15 symptomatic mutation carriers and 11 healthy non-mutation carriers. Expression of 752 miRNAs was measured using quantitative PCR (qPCR) arrays and validated by qPCR using individual primers. MiRNAs found differentially expressed in symptomatic compared with presymptomatic mutation carriers were further evaluated in a cohort of 17 patients with sporadic FTD, 13 patients with sporadic Alzheimer's disease (AD) and 10 healthy controls (HCs) of similar age. Results: In the GENFI cohort, miR-204-5p and miR-632 were significantly decreased in symptomatic compared with presymptomatic mutation carriers. Decrease of miR-204-5p and miR-632 revealed receiver operator characteristics with an area of 0.89 (90% CI 0.79 to 0.98) and 0.81 (90% CI 0.68 to 0.93), respectively, and when combined an area of 0.93 (90% CI 0.87 to 0.99). In sporadic FTD, only miR-632 was significantly decreased compared with AD and HCs. Decrease of miR-632 revealed an area of 0.90 (90% CI 0.81 to 0.98). Conclusions: Exosomal miR-204-5p and miR-632 have potential as diagnostic biomarkers for genetic FTD and miR-632 also for sporadic FTD.

Original languageEnglish
Pages (from-to)851-858
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume89
Issue number8
DOIs
Publication statusPublished - 2018

Fingerprint

Frontotemporal Dementia
Down-Regulation
Biomarkers
Mutation
MicroRNAs
Cerebrospinal Fluid
Exosomes
Polymerase Chain Reaction
Chromosomes, Human, Pair 9
Microtubule-Associated Proteins
Open Reading Frames
Alzheimer Disease

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Schneider, R., McKeever, P., Kim, T., Graff, C., Van Swieten, J. C., Karydas, A., ... Robertson, J. (2018). Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD: A GENFI study. Journal of Neurology, Neurosurgery and Psychiatry, 89(8), 851-858. https://doi.org/10.1136/jnnp-2017-317492

Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD : A GENFI study. / Schneider, Raphael; McKeever, Paul; Kim, Taehyung; Graff, Caroline; Van Swieten, John Cornelis; Karydas, Anna; Boxer, Adam; Rosen, Howie; Miller, Bruce L.; Laforce, Robert; Galimberti, Daniela; Masellis, Mario; Borroni, Barbara; Zhang, Zhaolei; Zinman, Lorne; Rohrer, Jonathan Daniel; Tartaglia, Maria Carmela; Robertson, Janice.

In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 89, No. 8, 2018, p. 851-858.

Research output: Contribution to journalArticle

Schneider, R, McKeever, P, Kim, T, Graff, C, Van Swieten, JC, Karydas, A, Boxer, A, Rosen, H, Miller, BL, Laforce, R, Galimberti, D, Masellis, M, Borroni, B, Zhang, Z, Zinman, L, Rohrer, JD, Tartaglia, MC & Robertson, J 2018, 'Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD: A GENFI study', Journal of Neurology, Neurosurgery and Psychiatry, vol. 89, no. 8, pp. 851-858. https://doi.org/10.1136/jnnp-2017-317492
Schneider, Raphael ; McKeever, Paul ; Kim, Taehyung ; Graff, Caroline ; Van Swieten, John Cornelis ; Karydas, Anna ; Boxer, Adam ; Rosen, Howie ; Miller, Bruce L. ; Laforce, Robert ; Galimberti, Daniela ; Masellis, Mario ; Borroni, Barbara ; Zhang, Zhaolei ; Zinman, Lorne ; Rohrer, Jonathan Daniel ; Tartaglia, Maria Carmela ; Robertson, Janice. / Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD : A GENFI study. In: Journal of Neurology, Neurosurgery and Psychiatry. 2018 ; Vol. 89, No. 8. pp. 851-858.
@article{914e513b83c246618b4ddf1f505b7476,
title = "Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD: A GENFI study",
abstract = "Objective: To determine whether exosomal microRNAs (miRNAs) in cerebrospinal fluid (CSF) of patients with frontotemporal dementia (FTD) can serve as diagnostic biomarkers, we assessed miRNA expression in the Genetic Frontotemporal Dementia Initiative (GENFI) cohort and in sporadic FTD. Methods: GENFI participants were either carriers of a pathogenic mutation in progranulin, chromosome 9 open reading frame 72 or microtubule-associated protein tau or were at risk of carrying a mutation because a first-degree relative was a known symptomatic mutation carrier. Exosomes were isolated from CSF of 23 presymptomatic and 15 symptomatic mutation carriers and 11 healthy non-mutation carriers. Expression of 752 miRNAs was measured using quantitative PCR (qPCR) arrays and validated by qPCR using individual primers. MiRNAs found differentially expressed in symptomatic compared with presymptomatic mutation carriers were further evaluated in a cohort of 17 patients with sporadic FTD, 13 patients with sporadic Alzheimer's disease (AD) and 10 healthy controls (HCs) of similar age. Results: In the GENFI cohort, miR-204-5p and miR-632 were significantly decreased in symptomatic compared with presymptomatic mutation carriers. Decrease of miR-204-5p and miR-632 revealed receiver operator characteristics with an area of 0.89 (90{\%} CI 0.79 to 0.98) and 0.81 (90{\%} CI 0.68 to 0.93), respectively, and when combined an area of 0.93 (90{\%} CI 0.87 to 0.99). In sporadic FTD, only miR-632 was significantly decreased compared with AD and HCs. Decrease of miR-632 revealed an area of 0.90 (90{\%} CI 0.81 to 0.98). Conclusions: Exosomal miR-204-5p and miR-632 have potential as diagnostic biomarkers for genetic FTD and miR-632 also for sporadic FTD.",
author = "Raphael Schneider and Paul McKeever and Taehyung Kim and Caroline Graff and {Van Swieten}, {John Cornelis} and Anna Karydas and Adam Boxer and Howie Rosen and Miller, {Bruce L.} and Robert Laforce and Daniela Galimberti and Mario Masellis and Barbara Borroni and Zhaolei Zhang and Lorne Zinman and Rohrer, {Jonathan Daniel} and Tartaglia, {Maria Carmela} and Janice Robertson",
year = "2018",
doi = "10.1136/jnnp-2017-317492",
language = "English",
volume = "89",
pages = "851--858",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group",
number = "8",

}

TY - JOUR

T1 - Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD

T2 - A GENFI study

AU - Schneider, Raphael

AU - McKeever, Paul

AU - Kim, Taehyung

AU - Graff, Caroline

AU - Van Swieten, John Cornelis

AU - Karydas, Anna

AU - Boxer, Adam

AU - Rosen, Howie

AU - Miller, Bruce L.

AU - Laforce, Robert

AU - Galimberti, Daniela

AU - Masellis, Mario

AU - Borroni, Barbara

AU - Zhang, Zhaolei

AU - Zinman, Lorne

AU - Rohrer, Jonathan Daniel

AU - Tartaglia, Maria Carmela

AU - Robertson, Janice

PY - 2018

Y1 - 2018

N2 - Objective: To determine whether exosomal microRNAs (miRNAs) in cerebrospinal fluid (CSF) of patients with frontotemporal dementia (FTD) can serve as diagnostic biomarkers, we assessed miRNA expression in the Genetic Frontotemporal Dementia Initiative (GENFI) cohort and in sporadic FTD. Methods: GENFI participants were either carriers of a pathogenic mutation in progranulin, chromosome 9 open reading frame 72 or microtubule-associated protein tau or were at risk of carrying a mutation because a first-degree relative was a known symptomatic mutation carrier. Exosomes were isolated from CSF of 23 presymptomatic and 15 symptomatic mutation carriers and 11 healthy non-mutation carriers. Expression of 752 miRNAs was measured using quantitative PCR (qPCR) arrays and validated by qPCR using individual primers. MiRNAs found differentially expressed in symptomatic compared with presymptomatic mutation carriers were further evaluated in a cohort of 17 patients with sporadic FTD, 13 patients with sporadic Alzheimer's disease (AD) and 10 healthy controls (HCs) of similar age. Results: In the GENFI cohort, miR-204-5p and miR-632 were significantly decreased in symptomatic compared with presymptomatic mutation carriers. Decrease of miR-204-5p and miR-632 revealed receiver operator characteristics with an area of 0.89 (90% CI 0.79 to 0.98) and 0.81 (90% CI 0.68 to 0.93), respectively, and when combined an area of 0.93 (90% CI 0.87 to 0.99). In sporadic FTD, only miR-632 was significantly decreased compared with AD and HCs. Decrease of miR-632 revealed an area of 0.90 (90% CI 0.81 to 0.98). Conclusions: Exosomal miR-204-5p and miR-632 have potential as diagnostic biomarkers for genetic FTD and miR-632 also for sporadic FTD.

AB - Objective: To determine whether exosomal microRNAs (miRNAs) in cerebrospinal fluid (CSF) of patients with frontotemporal dementia (FTD) can serve as diagnostic biomarkers, we assessed miRNA expression in the Genetic Frontotemporal Dementia Initiative (GENFI) cohort and in sporadic FTD. Methods: GENFI participants were either carriers of a pathogenic mutation in progranulin, chromosome 9 open reading frame 72 or microtubule-associated protein tau or were at risk of carrying a mutation because a first-degree relative was a known symptomatic mutation carrier. Exosomes were isolated from CSF of 23 presymptomatic and 15 symptomatic mutation carriers and 11 healthy non-mutation carriers. Expression of 752 miRNAs was measured using quantitative PCR (qPCR) arrays and validated by qPCR using individual primers. MiRNAs found differentially expressed in symptomatic compared with presymptomatic mutation carriers were further evaluated in a cohort of 17 patients with sporadic FTD, 13 patients with sporadic Alzheimer's disease (AD) and 10 healthy controls (HCs) of similar age. Results: In the GENFI cohort, miR-204-5p and miR-632 were significantly decreased in symptomatic compared with presymptomatic mutation carriers. Decrease of miR-204-5p and miR-632 revealed receiver operator characteristics with an area of 0.89 (90% CI 0.79 to 0.98) and 0.81 (90% CI 0.68 to 0.93), respectively, and when combined an area of 0.93 (90% CI 0.87 to 0.99). In sporadic FTD, only miR-632 was significantly decreased compared with AD and HCs. Decrease of miR-632 revealed an area of 0.90 (90% CI 0.81 to 0.98). Conclusions: Exosomal miR-204-5p and miR-632 have potential as diagnostic biomarkers for genetic FTD and miR-632 also for sporadic FTD.

UR - http://www.scopus.com/inward/record.url?scp=85049045055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049045055&partnerID=8YFLogxK

U2 - 10.1136/jnnp-2017-317492

DO - 10.1136/jnnp-2017-317492

M3 - Article

AN - SCOPUS:85049045055

VL - 89

SP - 851

EP - 858

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

IS - 8

ER -